Structural optimization of adaptaquin, a HIF prolyl hydroxylase inhibitor


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The structural optimization of adaptaquin, viz., 7-(4-chlorophenyl)[(3-hydroxypyridin-2-yl)amino]methylquinolin-8-ol, a HIF (hypoxia inducible factor) prolyl hydroxylase inhibitor, was carried out. This was done by cell-based screening using cell lines stably expressing a reporter construct consisting of the fusion protein of HIF oxygen-dependent domain and firefly luciferase (HIF1 ODD-luc). More than 100 structural analogs of adaptaquin were screened and the structures active in the submicromolar range were selected. The highest activity was found for analogs containing isobutyl, isopropyl, trifluoromethyl, and nitro group or halogen atom in the para-position of the benzene ring, but not a dimethylamino group or more bulky substituents. The lack of dependence on the donor-acceptor properties of substituents attests to predominance of the steric effect. The presence of methyl group in positions 3 and 5 of the pyridine ring provides additional activation. The 2-methyl group present in the hydroxyquinoline scaffold (50 compounds in the set) prevents coordination of the inhibitor in the active site and significantly reduces the activation. According to the real-time PCR results, the newly improved adaptaquin analog induces HIF target genes 15-times more efficiently than the FG-4592 inhibitor developed by Fibrogen.

Sobre autores

A. Osipyants

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Rússia, 1 ul. Samory Mashela, Moscow, 117997

V. Tishkov

Department of Chemistry, M. V. Lomonosov Moscow State University; Innovations and High Technologies MSU Ltd.; A. N. Bach Institute of Biochemistry, Russian Academy of Sciences, Federal Research Center “Fundamentals of Biotechnology”

Email: andrey.poloznikov@fccho-moscow.ru
Rússia, Build 3, 1 Leninskie Gory, Moscow, 119991; 16 ul. Tsymlyanskaya, Moscow, 109451; Build. 2, 33 Leninsky prosp., Moscow, 119071

I. Gazaryan

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology; Department of Chemistry, M. V. Lomonosov Moscow State University

Email: andrey.poloznikov@fccho-moscow.ru
Rússia, 1 ul. Samory Mashela, Moscow, 117997; Build 3, 1 Leninskie Gory, Moscow, 119991

A. Poloznikov

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology; National Medical Research Radiological Center, Ministry of Health of the Russian Federation

Autor responsável pela correspondência
Email: andrey.poloznikov@fccho-moscow.ru
Rússia, 1 ul. Samory Mashela, Moscow, 117997; 4 ul. Koroleva, Obninsk, 249036

A. Khristichenko

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Rússia, 1 ul. Samory Mashela, Moscow, 117997

N. Smirnova

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Rússia, 1 ul. Samory Mashela, Moscow, 117997

D. Hushpulian

Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology

Email: andrey.poloznikov@fccho-moscow.ru
Rússia, 1 ul. Samory Mashela, Moscow, 117997

I. Gaisina

Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago

Email: andrey.poloznikov@fccho-moscow.ru
Estados Unidos da América, 833 South Wood, Chicago, IL, 60612

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2019